Blastoma: Cancers from Embryonic Cells—Types, Diagnosis & Treatment
What Is a Blastoma?
Blastoma is a malignant tumor arising from immature precursor cells (blasts) during embryonic or fetal development. The suffix "-blastoma" indicates cell origin (e.g., neuroblast → neuroblastoma). These are predominantly **pediatric cancers**.
Major Types
| Blastoma | Cell Origin | Typical Age | Primary Site | Key Features |
|---|---|---|---|---|
| Medulloblastoma | Neural precursors | Children (3–8 yrs) | Cerebellum (posterior fossa) | Most common malignant pediatric brain tumor; spreads via CSF |
| Neuroblastoma | Sympathetic neuroblasts | Infants/young children | Adrenal gland, abdomen, chest | Variable behavior: spontaneous regression to aggressive metastasis; MYCN amplification = poor prognosis |
| Retinoblastoma | Retinal precursors | <5 years | Retina | Heritable (RB1 germline) or sporadic; leukocoria (white pupil) hallmark |
| Nephroblastoma (Wilms Tumor) | Renal blastema | 2–5 years | Kidney | Most common pediatric renal cancer; associated with WAGR, Beckwith-Wiedemann syndromes |
| Hepatoblastoma | Hepatic precursors | <3 years | Liver | Most common pediatric liver cancer; AFP tumor marker |
| Germ Cell Tumors | Primordial germ cells | Children & young adults | Gonads (testis/ovary), sacrococcygeal, mediastinum | Seminoma, yolk sac tumor, teratoma; AFP/β-hCG markers |
| Pleuropulmonary Blastoma | Lung mesenchymal | Young children | Lung/pleura | Rare; associated with DICER1 mutation |
Diagnosis
- Imaging: MRI (brain), CT/US (abdomen), PET-CT (staging)
- Biopsy: Histopathology + immunohistochemistry
- Molecular: MYCN, RB1, CTNNB1, DICER1, etc.
- Markers: AFP, β-hCG, NSE, LDH
- Bone marrow aspirate/biopsy (neuroblastoma, germ cell)
- Lumbar puncture (medulloblastoma, retinoblastoma)
Treatment: Multimodal & Risk-Adapted
- Surgery: Resection (goal: gross total); biopsy if unresectable.
- Chemotherapy: Multi-agent protocols (e.g., COG, SIOP, GPOH); neoadjuvant or adjuvant.
- Radiation: For residual/local control; proton therapy reduces late effects.
- High-dose chemo + stem cell rescue: High-risk neuroblastoma, germ cell.
- Targeted/Immunotherapy: Anti-GD2 (dinutuximab) for neuroblastoma; checkpoint inhibitors in trials.
Prognosis & Survivorship
Varies dramatically by type, stage, molecular profile. Many have >80–90% cure rates (Wilms, low-risk neuroblastoma, retinoblastoma). Long-term follow-up essential for late effects: cardiotoxicity, neurocognitive, endocrine, second malignancies.
Lymphoma - Related Articles
- MALT Lymphoma: Understanding Diagnosis, Symptoms & Treatment
- FDG PET for Cancer Diagnosis and Treatment Planning
- Lymphocytes: Types, Functions, and Role in Immune Defense
- B Cell vs. T Cell Development: Lineage Commitment in the Bone Marrow and Thymus
- Lymphatic System: How Lymph Fluid Circulates Through Vessels and Nodes
- B-Cell Lymphoma: Types, Diagnosis & Modern Treatment
- FLIPI Score for Follicular Lymphoma: Understanding Prognosis
